Skip to NavigationSkip to content

Business Services

Crescendo Biologics selects current CFO Theodora Harold as new CEO

Published on: 04/04/19

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack as the company’s new CEO.

Cambridge University graduate Harold will succeed Dr Pack at the beginning of next month, after he steps down from his current position on 1 May 2019.

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

Image Credit: NHS Confederation

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA Times.  

The legal action comes after Sorrento accused Soon-Shiong of “catching and killing” a generic version of a cancer drug, which would have acted as competition to one owned by Celgene, a company in which he was the largest shareholder.

Sorrento claim Soon-Shiong acquired Cynviloq, a generic version of Celgene’s Abraxane, with the intention of stopping its progression to market.

Artios Pharma name experienced oncologist as company's new CMO

Published on: 01/04/19

British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO).

Dr Smith will join the Cambridge-based firm – which is focused on DNA Damage Response (DDR) as a treatment for cancer – as he takes responsibility for Artios’s overall preclinical and clinical development strategy, as well as the firm’s regulatory and medical activities.

Having graduated with a degree in medicine in 1992, Dr Smith brings more than 16 years of pharmaceutical industry experience to Artios.

How I learned to stop worrying and love the placebo effect

Published on 01/04/19 at 11:44am

Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for doctors, patients and pharmaceutical companies in clinical trials.

On 14 February 2019, Danish firm Lundbeck and its Japanese partner Otsuka announced the results of two Phase 3 trials looking into the effectiveness of their previously successful antipsychotic, Rexulti (brexpiprazole), as a treatment for manic episodes associated with bipolar I disorder.

Top Ten most popular articles on this week!

A Japanese journalist was ordered to pay ¥3.3 million to an anti-vaccine researcher, this week, after a court found her guilty of libel. The case is being taken as a major setback for those fighting misinformation surrounding vaccines.

Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering

Published on 28/03/19 at 11:18am

Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.

How did you first find your way into the pharmaceutical industry?

Conducting internal investigations within a pharmaceutical business

Published on 25/03/19 at 11:27am

Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a robust strategy to tackle such an undertaking.

When a concern about serious wrongdoing arises within a pharmaceutical business, the company needs to react fast. One of its first priorities will be to understand the issue fully in order to determine its reaction. Undertaking an internal investigation is a critical part of that process.

Top Ten most popular articles on this week!

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on hold after a number of patient deaths; Biogen and Eisai pulled a study of an Alzheimer’s drug after forecasts showed it wasn’t likely to succeed. Pfizer and Merck then discontinued a Phase 3 trial of avelumab as a treatment for advanced ovarian cancer in combination with chemotherapy.

Breathing life into COPD research

Published on 21/03/19 at 11:59am

Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD to help ensure UK patients receive the best care.

Helpless. Like drowning. Like suffocating. This is how people with chronic obstructive pulmonary disease (COPD) have described what having this disease feels like.

Patient Experience: Living with two rare diseases

Published on 18/03/19 at 12:03pm

Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. But this occurrence, at a prevalence of one in 70 million, was compounded later in life when he found he was living with not one, but two rare conditions, complicating treatment and leading to some very close calls.

How did you originally come to be diagnosed with Wyburn-Mason syndrome?

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches